# Agenus (AGEN) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/AGEN
## Company Profile
- Ticker: AGEN
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
- Tags: Immunotherapy, Oncology
## Stock Data
- Close: 7.43 USD
- Market cap: 140751416.78 USD
- Last updated: 2026-09-08
## Business Overview
Agenus is an immuno-oncology company focused on cancer immunotherapy, including checkpoint and combination approaches. The company has spent years trying to turn immune science into a durable oncology franchise.
## Why The Stock Is Moving

As of Sep 8, 2026, AGEN closed down 9.83% at $7.43. No new same-company headline was identified in the current news window.

## Geographic Base

Headquartered in the United States and listed on NASDAQ, Agenus sits in specialty oncology biotechnology.

## Business Model

The business depends on clinical data, strategic partnerships, and the ability to translate immunotherapy science into value.

## Landscape Position

Agenus is a high-risk oncology name whose valuation is heavily dependent on clinical and strategic milestones.

## Future Catalysts

- Agenus's catalysts are botensilimab and balstilimab combination data, plus any partnering progression that can de-risk the program. The company still needs proof that the immuno-oncology story can keep moving.

## Recent News
- 2023-03-14 11:30 EST — [Agenus Reports Fourth Quarter and Full Year 2022 Financial Results and Outlines 2023 Objectives](https://biopharmsignal.com/news/AGEN/agenus-reports-fourth-quarter-and-full-year-2022-financial-results-and-outlines--e71b327e) — Source: Agenus
- 2023-03-13 00:29 EST — [Agenus Cancels Conference Call to Discuss the Company’s Minority Cash Holdings at SVB in Light of Government’s SVB Deposit Access Announcement](https://biopharmsignal.com/news/AGEN/agenus-cancels-conference-call-to-discuss-the-company-s-minority-cash-holdings-a-4a1ea060) — Source: Agenus
- 2023-03-11 16:24 EST — [Agenus Schedules Conference Call to Discuss the Company’s Minority Cash Holdings at SVB](https://biopharmsignal.com/news/AGEN/agenus-schedules-conference-call-to-discuss-the-company-s-minority-cash-holdings-81c788dd) — Source: Agenus
- 2023-02-28 12:30 EST — [Agenus to Present Botensilimab Data in Oral Plenary Session at the Society of Gynecologic Oncology 2023 Annual Meeting on Women’s Cancer](https://biopharmsignal.com/news/AGEN/agenus-to-present-botensilimab-data-in-oral-plenary-session-at-the-society-of-gy-3e78eefb) — Source: Agenus
- 2023-02-28 12:30 EST — [Agenus to Provide Corporate Update and Fourth Quarter & Full Year 2022 Financial Report](https://biopharmsignal.com/news/AGEN/agenus-to-provide-corporate-update-and-fourth-quarter-full-year-2022-financial-r-3c9f7549) — Source: Agenus